Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04976634 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

A Phase 2 study of Neoplasm Malignant, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
730
Enrollment target
20
Study locations

NCT04976634 is a Phase 2 study of Neoplasm Malignant that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 730 participants, above the 187-participant average among 7 other Neoplasm Malignant trials with a reported enrollment target (290% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04976634, a Phase 2 study of Neoplasm Malignant, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
730 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

Conditions Studied

Neoplasm Malignant

Interventions

  • DRUG Pembrolizumab
  • DRUG Belzutifan
  • DRUG Lenvatinib

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center ( Site 5002) - Duarte
  • Cedars-Sinai Medical Center ( Site 5045) - Los Angeles
  • UCSF Medical Center at Mission Bay ( Site 5021) - San Francisco

Virginia

  • Inova Schar Cancer Institute ( Site 5039) - Fairfax
  • Blue Ridge Cancer Care ( Site 5053) - Roanoke

New South Wales

  • Gosford Hospital-Oncology Trials ( Site 4004) - Gosford
  • Westmead Hospital-Department of Medical Oncology ( Site 4001) - Westmead

Victoria

  • Northern Hospital-Department of Medical Oncology ( Site 4003) - Epping
  • Cabrini Hospital - Malvern-Cabrini Institute ( Site 4000) - Malvern

Arizona

  • University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047) - Tucson

Connecticut

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 5013) - New Haven

District of Columbia

  • Sibley Memorial Hospital ( Site 5051) - Washington D.C.

Florida

  • University of Florida College of Medicine ( Site 5015) - Gainesville

Trial Details

FieldValue
Enrollment Target 730 participants
Start Date 2021-08-18
Est. Completion 2027-03-22
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04976634

The ClinicalTrials.gov registry entry for NCT04976634 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 7 other Neoplasm Malignant trials with a reported enrollment target (290% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasm Malignant appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT04976634 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Virginia, New South Wales.

Frequently Asked Questions

What is clinical trial NCT04976634 about?

NCT04976634 is a clinical study titled "Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)". The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometria...

What is the current status of trial NCT04976634?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 730 participants. The study started on 2021-08-18. Estimated completion is 2027-03-22.

What conditions does trial NCT04976634 study?

This clinical trial studies the following conditions: Neoplasm Malignant.

What interventions are being tested in trial NCT04976634?

The interventions under investigation include: Pembrolizumab (DRUG), Belzutifan (DRUG), Lenvatinib (DRUG).

Who is sponsoring clinical trial NCT04976634?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04976634 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Malignant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm Malignant

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.